Japan has given partial go-ahead to the globe’s initial therapeutic agent targeting Parkinson’s disease, which utilizes induced pluripotent stem cells (iPS cells). This announcement came from the Center for iPS Cell Research and Application at Kyoto University.
Marketed under the name Amshepuri, this treatment comprises neural cells intended for transplantation into patients. The clinical trials concluded in April 2025 demonstrated favorable outcomes for a segment of the trial participants.
The submission seeking approval was filed by the pharmaceutical company Sumitomo Pharma in August of the preceding year and underwent an expedited review process.
Jun Takahashi, the institute’s director, characterized this as a pivotal milestone, pledging to transform this therapy into a routine treatment modality.
About the Author
